OncoMatch/Clinical Trials/NCT06558227

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Is NCT06558227 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ZG005 for and Bevacizumab for hepatocellular carcinoma.

Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT06558227Data as of May 2026

Treatment: ZG005 for · Bevacizumab · Sintilimab · Bevacizumab — This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify